Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Prostate Cancer Treatment and Research, Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, and Cancer Genomics and Diagnostics.
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types
Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies
Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Evolving Global Trends in Prostate Cancer: Disparities Across Income Levels and Geographic Regions (1990-2019)
The prognostic role of circulating tumor DNA (ctDNA) clearance as a biomarker in localized and metastatic renal cell carcinoma (RCC): A single-center experience.
Prostate Cancer, Version 3.2024
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
Robustness of cancer microbiome signals over a broad range of methodological variation
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review
Androgen receptor pathway inhibitors and drug–drug interactions in prostate cancer
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations
Pan-Cancer Interrogation of B7-H3 ( <i>CD276</i> ) as an Actionable Therapeutic Target Across Human Malignancies
Retraction Note: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma